27 results about "Ventricular tachycardia" patented technology

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

Ventricle-from-atrium (VfA) devices, systems, and methods may be configured to detect a tachyarrhythmia. For in-stance, an atrial event rate may be compared to a ventricular rate to determine whether a patient's heart is undergoing a tachyarrhythmia. Further, it may be determined whether the tachyarrhythmia is a supraventricular tachycardia or ventricular tachycardia prior to delivering therapy to treat the tachyarrhythmia.

A method includes applying pacing to ventricle of heart of patient from multiple electrode locations over circumference of multi-electrode catheter area. Cardiac signals are received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations among the received signals. Based on calculated correlations, the area is checked if it includes an arrhythmogenic location identified with predefined sufficient spatial resolution. If the resolution is insufficient, sub-area to pace is defined. Subsequent pacing is applied to ventricle from multiple electrode locations over a circumference of the sub-area. Subsequent cardiac signals are received in response to the subsequent pacing. Subsequent correlations among the subsequent received signals are calculated. Based on the subsequent correlations, it is ascertained whether the arrhythmogenic location is found in the sub-area. If an arrhythmogenic location is found with sufficient spatial resolution, the identified arrhythmogenic location is indicated to user.

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to a given tissue location inside a ventricle of a heart of a patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space with respect to an origin located in the heart. The processor is configured to (i) compute a set of respective signal differences between the acquired set of ECG signals and a reference set of ECG signals, (ii) compute a set of corresponding deviation vectors along the respective directions in the space, the deviation vectors having magnitudes corresponding to the respective signal differences, (iii) using the deviation vectors, compute a direction vector from the given location to a new ventricle location at which to apply the pacing, and (iv) indicate the computed direction vector to a user.

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Embodiments of a wearable cardioverter defibrillator (WCD) system include a support structure for wearing by an ambulatory patient, a posture detector and at least one processor. When worn, the support structure maintains electrodes on the patient's body, and using the posture detector and the patient's ECG received via the electrodes, the processor determines the patient's posture, formulates posture-based templates of QRS complexes, and the patient's heart rate. The processor can use these determinations to distinguish between VT and SVT and make no-shock, and shock decisions.

The invention relates to identification of ventricular tachycardia (VT) targets by selective pacing. A method includes applying pacing to a ventricle of a heart of a patient from a plurality of electrode locations on a circumference of a multi-electrode catheter region. A cardiac signal is received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations between the received signals. Based on the calculated correlation, it is checked whether the region includes an arrhythmic location identified at a predefined sufficient spatial resolution. If the resolution is insufficient, the sub-region to be paced is defined. Subsequent pacing is applied to the ventricle from a plurality of electrode locations on the circumference of the sub-region. A subsequent cardiac signal is received in response to the subsequent pacing. A subsequent correlation between the subsequently received signals is calculated. Based on the subsequent correlations, it is determined whether to find the arrhythmic location in the sub-region. If an arrhythmic location is found with sufficient spatial resolution, the identified arrhythmic location is indicated to the user.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

A system for VT localization comprises an electrocardiograph (ECG) device for detecting electrical signals of a ventricular fibrillation event in a patient and producing ECG data, a localizer, and a display device. The localizer comprises a memory and a processor, the memory storing a model and one or more parameters of the model. The memory further stores instructions that when executed by the processor cause the processor to receive the ECG data, and generate a determination indicating whether a detected VT signal arose from an endocardial surface or epicardial surface based on signal averaged waveform for each of the leads. The display device is configured to output the determination, which can also be communicated to follow-on provider systems.

An ambulatory medical device configured to be worn on a patient's body includes at least one electrocardiogram (ECG) electrode configured to sense cardiac activity, at least one acoustic sensor configured to detect one or more heart sounds, and at least one processor. The at least one processor is configured to implement a cardiopulmonary function analyzer to detect a suspected tachyarrhythmia based on an analysis of ECG signal(s) and verify the suspected tachyarrhythmia as a ventricular tachycardia (VT) event by analyzing acoustic signal(s) to distinguish the VT event from a supraventricular tachycardia (SVT) event. Said analysis includes determining an intensity and / or a beat-to-beat variability of a first heart sound (S1). The at least one processor verifies the suspected tachyarrhythmia as the VT event when the intensity of the S1 sound is below a predetermined intensity threshold or when the beat-to-beat variability of the S1 sound is above a predetermined variability threshold.

To evaluate electrical propagation in a heart.SOLUTION: A method for evaluation of electrical propagation in the heart includes receiving a pacing signal applied to a heart of a patient, the pacing signal including a normal sequence and shorter abnormal pacing stimuli. A responsive cardiac signal is received, which is sensed by electrodes at a location in the heart and on a body surface of the patient. A model response is found and annotated from evoked potentials caused by the normal pacing stimuli. A correlation is made between the model responses along the different signal sections to find and calculate a normal time delay and a decremental time delay between the pacing stimuli and respectively resulting evoked potentials at a tissue location. A time difference is calculated, between the normal time delay and the decremental time delay. An EP map of at least a portion of the heart is presented to a user, with a graphical indication of the time difference presented at the tissue location.SELECTED DRAWING: Figure 1

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

This disclosure generally relates to systems, devices, and methods for initiating or inhibiting noise reversion pacing therapy based on a morphology analysis to determine whether monitored cardiac electrical activity is indicative of a ventricular tachycardia / ventricular fibrillation (VT / VF). Specifically, if the morphology analysis indicates that a VT / VF episode is occurring, then noise reversion pacing therapy is inhibited.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

To provide a cardiopulmonary resuscitation (CPR) support device that can estimate a cause of cardiopulmonary arrest other than ventricular fibrillation and ventricular tachycardia during CPR using an automated external defibrillator. [Solution] A cardiopulmonary resuscitation support device that is built into an automated external defibrillator or used in combination with an automated external defibrillator, and is equipped with an estimation means for estimating a cause of cardiopulmonary arrest other than ventricular fibrillation and ventricular tachycardia during cardiopulmonary resuscitation.

To provide a method for evaluation of electrical propagation in the heart.SOLUTION: A method includes applying pacing to ventricle of heart of patient from multiple electrode locations over circumference of multi-electrode catheter area. Cardiac signals are received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations among the received signals. Based on calculated correlations, the area is checked if it includes an arrhythmogenic location identified with predefined sufficient spatial resolution. If the resolution is insufficient, sub-area to pace is defined. Subsequent pacing is applied to ventricle from multiple electrode locations over a circumference of the sub-area. Subsequent cardiac signals are received in response to the subsequent pacing. Subsequent correlations among the subsequent received signals are calculated. Based on the subsequent correlations, it is ascertained whether the arrhythmogenic location is found in the sub-area. If an arrhythmogenic location is found with sufficient spatial resolution, the identified arrhythmogenic location is indicated to user.SELECTED DRAWING: Figure 1

The invention provides a fatal ventricular tachycardia detection system based on independent weight updating, and relates to the technical field of fatal arrhythmia detection.The fatal ventricular tachycardia detection system comprises a data acquisition module used for acquiring original heart sound data and preprocessing the original heart sound data to obtain signal fragments; the model reasoning module is used for inputting the signal frequency band into a multi-outlet neural network reasoning model, calculating the confidence coefficient of a prediction result of a current network outlet, judging whether the current network outlet is a final outlet or not according to the confidence coefficient, and if not, continuing to go to the next network outlet to obtain a prediction result with higher precision; wherein multiple layers of backbone networks are arranged in the multi-outlet neural network inference model, each layer of backbone network corresponds to one network outlet, the weight of each layer of backbone network is optimized and finely adjusted through an independent weight updating algorithm, and efficient personalized tachycardia detection of the multi-outlet neural network inference model is achieved. According to the system disclosed by the invention, the detection accuracy of the fatal ventricular tachycardia is improved.

This invention provides a condensed heteroaryl compound having CaMKII inhibitory activity, which is expected to be useful as a drug for the prevention or treatment of heart diseases (particularly catecholamine-induced polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, and fatal arrhythmias). [Solution] Formula (I): JPEG2026086814000103.jpg5175 A compound represented by or a pharmaceutically acceptable salt thereof is provided.

The present invention relates to a compound of formula (I), as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.